NRX Pharmaceuticals (STU:B1Q) Pre-Tax Income : €-23.70 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is NRX Pharmaceuticals Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. NRX Pharmaceuticals's pretax income for the three months ended in Mar. 2024 was €-6.01 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was €-23.70 Mil. NRX Pharmaceuticals's pretax margin was %.

NRX Pharmaceuticals Pre-Tax Income Historical Data

The historical data trend for NRX Pharmaceuticals's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals Pre-Tax Income Chart

NRX Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

-42.56

-82.36

-37.53

-27.65

NRX Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Pre-Tax Income	Get a 7-Day Free Trial											-10.31	-8.05	-5.68	-3.97	-6.01

Competitive Comparison of NRX Pharmaceuticals's Pre-Tax Income

For the Biotechnology subindustry, NRX Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NRX Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where NRX Pharmaceuticals's Pre-Tax Income falls into.

NRX Pharmaceuticals Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

NRX Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-25.527	+	-2.464	+	-0.11	+	0.453	+	0
	=	-27.65

NRX Pharmaceuticals's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-5.518	+	-0.301	+	-0.212	+	0.025	+	-8.8817841970013E-16
	=	-6.01

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-23.70 Mil.

NRX Pharmaceuticals (STU:B1Q) Pre-Tax Income Explanation

NRX Pharmaceuticals's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-6.006	/	0
	=	%

NRX Pharmaceuticals Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

NRX Pharmaceuticals (STU:B1Q) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (STU:B1Q) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

NRXP:USA

Address

1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801

Website

https://nrxpharma.com

NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.

NRX Pharmaceuticals (STU:B1Q) Headlines

No Headlines